OBJECTIVES: Ex vivo lung perfusion (EVLP) is a promising modality for the evaluation and treatment of marginal donor lungs. The optimal timing of EVLP initiation and the potential for rehabilitation of donor lungs with extended warm ischemic times is unknown. The present study compared the efficacy of different treatment strategies for uncontrolled non-heart-beating donor lungs. METHODS: Mature swine underwent hypoxic arrest, followed by 60 minutes of no-touch warm ischemia. The lungs were harvested and flushed with 4°C Perfadex. Three groups (n = 5/group) were stratified according to the preservation method: cold static preservation (CSP; 4 hours of 4°C storage), immediate EVLP (I-EVLP: 4 hours EVLP at 37°C), and delayed EVLP (D-EVLP; 4 hours of CSP followed by 4 hours of EVLP). The EVLP groups were perfused with Steen solution supplemented with heparin, methylprednisolone, cefazolin, and an adenosine 2A receptor agonist. The lungs then underwent allotransplantation and 4 hours of recipient reperfusion before allograft assessment for resultant ischemia-reperfusion injury. RESULTS: The donor blood oxygenation (partial pressure of oxygen/fraction of inspired oxygen ratio) before death was not different between the groups. The oxygenation after transplantation was significantly greater in the D-EVLP group than in the I-EVLP or CSP groups. The mean airway pressure, pulmonary artery pressure, and expression of interleukin-8, interleukin-1β, and tumor necrosis factor-α were all significantly reduced in the D-EVLP group. Post-transplant oxygenation exceeded the acceptable clinical levels only in the D-EVLP group. CONCLUSIONS: Uncontrolled non-heart-beating donor lungs with extended warm ischemia can be reconditioned for successful transplantation. The combination of CSP and EVLP in the D-EVLP group was necessary to obtain optimal post-transplant function. This finding, if confirmed clinically, will allow expanded use of nonheart-beating donor lungs.
OBJECTIVES: Ex vivo lung perfusion (EVLP) is a promising modality for the evaluation and treatment of marginal donor lungs. The optimal timing of EVLP initiation and the potential for rehabilitation of donor lungs with extended warm ischemic times is unknown. The present study compared the efficacy of different treatment strategies for uncontrolled non-heart-beating donor lungs. METHODS: Mature swine underwent hypoxic arrest, followed by 60 minutes of no-touch warm ischemia. The lungs were harvested and flushed with 4°C Perfadex. Three groups (n = 5/group) were stratified according to the preservation method: cold static preservation (CSP; 4 hours of 4°C storage), immediate EVLP (I-EVLP: 4 hours EVLP at 37°C), and delayed EVLP (D-EVLP; 4 hours of CSP followed by 4 hours of EVLP). The EVLP groups were perfused with Steen solution supplemented with heparin, methylprednisolone, cefazolin, and an adenosine 2A receptor agonist. The lungs then underwent allotransplantation and 4 hours of recipient reperfusion before allograft assessment for resultant ischemia-reperfusion injury. RESULTS: The donor blood oxygenation (partial pressure of oxygen/fraction of inspired oxygen ratio) before death was not different between the groups. The oxygenation after transplantation was significantly greater in the D-EVLP group than in the I-EVLP or CSP groups. The mean airway pressure, pulmonary artery pressure, and expression of interleukin-8, interleukin-1β, and tumor necrosis factor-α were all significantly reduced in the D-EVLP group. Post-transplant oxygenation exceeded the acceptable clinical levels only in the D-EVLP group. CONCLUSIONS: Uncontrolled non-heart-beating donor lungs with extended warm ischemia can be reconditioned for successful transplantation. The combination of CSP and EVLP in the D-EVLP group was necessary to obtain optimal post-transplant function. This finding, if confirmed clinically, will allow expanded use of nonheart-beating donor lungs.
Authors: David Gomez-de-Antonio; Jose Luis Campo-Cañaveral; Silvana Crowley; Daniel Valdivia; Mar Cordoba; Javier Moradiellos; Jose Manual Naranjo; Piedad Ussetti; Andrés Varela Journal: J Heart Lung Transplant Date: 2012-02-03 Impact factor: 10.247
Authors: Marcelo Cypel; Jonathan C Yeung; Mingyao Liu; Masaki Anraku; Fengshi Chen; Wojtek Karolak; Masaaki Sato; Jane Laratta; Sassan Azad; Mindy Madonik; Chung-Wai Chow; Cecilia Chaparro; Michael Hutcheon; Lianne G Singer; Arthur S Slutsky; Kazuhiro Yasufuku; Marc de Perrot; Andrew F Pierre; Thomas K Waddell; Shaf Keshavjee Journal: N Engl J Med Date: 2011-04-14 Impact factor: 91.245
Authors: Abbas Emaminia; Damien J Lapar; Yunge Zhao; John F Steidle; David A Harris; Victor E Laubach; Joel Linden; Irving L Kron; Christine L Lau Journal: Ann Thorac Surg Date: 2011-10-31 Impact factor: 4.330
Authors: Damien J LaPar; Victor E Laubach; Abbas Emaminia; Ivan K Crosby; Vanessa A Hajzus; Ashish K Sharma; Heather M Sumner; David V Webb; Christine L Lau; Irving L Kron Journal: J Thorac Cardiovasc Surg Date: 2011-07-16 Impact factor: 5.209
Authors: M Cypel; M Rubacha; J Yeung; S Hirayama; K Torbicki; M Madonik; S Fischer; D Hwang; A Pierre; T K Waddell; M de Perrot; M Liu; S Keshavjee Journal: Am J Transplant Date: 2009-08-06 Impact factor: 8.086
Authors: Krisztina Köröskényi; Edina Duró; Anna Pallai; Zsolt Sarang; Doris Kloor; David S Ucker; Susana Beceiro; Antonio Castrillo; Ajay Chawla; Catherine A Ledent; László Fésüs; Zsuzsa Szondy Journal: J Immunol Date: 2011-05-18 Impact factor: 5.422
Authors: Ashish K Sharma; Victor E Laubach; Susan I Ramos; Yunge Zhao; George Stukenborg; Joel Linden; Irving L Kron; Zequan Yang Journal: J Thorac Cardiovasc Surg Date: 2009-11-11 Impact factor: 5.209
Authors: Jared P Beller; Matthew R Byler; Dustin T Money; William Z Chancellor; Aimee Zhang; Yunge Zhao; Mark H Stoler; Adishesh K Narahari; Alexander Shannon; J Hunter Mehaffey; Curtis G Tribble; Victor E Laubach; Irving L Kron; Mark E Roeser Journal: J Heart Lung Transplant Date: 2019-09-18 Impact factor: 10.247
Authors: Vibha N Lama; John A Belperio; Jason D Christie; Souheil El-Chemaly; Michael C Fishbein; Andrew E Gelman; Wayne W Hancock; Shaf Keshavjee; Daniel Kreisel; Victor E Laubach; Mark R Looney; John F McDyer; Thalachallour Mohanakumar; Rebecca A Shilling; Angela Panoskaltsis-Mortari; David S Wilkes; Jerry P Eu; Mark R Nicolls Journal: JCI Insight Date: 2017-05-04
Authors: J Hunter Mehaffey; Eric J Charles; Ashish K Sharma; Dustin T Money; Yunge Zhao; Mark H Stoler; Christine L Lau; Curtis G Tribble; Victor E Laubach; Mark E Roeser; Irving L Kron Journal: J Thorac Cardiovasc Surg Date: 2016-09-22 Impact factor: 5.209
Authors: Achilleas Thoma; Forough Farrokhyar; Daniel Waltho; Luis H Braga; Sheila Sprague; Charlie H Goldsmith Journal: Can J Surg Date: 2017-12 Impact factor: 2.089
Authors: Eric J Charles; J Hunter Mehaffey; Ashish K Sharma; Yunge Zhao; Mark H Stoler; James M Isbell; Christine L Lau; Curtis G Tribble; Victor E Laubach; Irving L Kron Journal: J Thorac Cardiovasc Surg Date: 2017-04-12 Impact factor: 5.209
Authors: J Hunter Mehaffey; Eric J Charles; Ashish K Sharma; Morgan Salmon; Dustin Money; Sarah Schubert; Mark H Stoler; Curtis G Tribble; Victor E Laubach; Mark E Roeser; Irving L Kron Journal: Ann Thorac Surg Date: 2017-04-21 Impact factor: 4.330
Authors: Cynthia E Wagner; Nicolas H Pope; Eric J Charles; Mary E Huerter; Ashish K Sharma; Morgan D Salmon; Benjamin T Carter; Mark H Stoler; Christine L Lau; Victor E Laubach; Irving L Kron Journal: J Thorac Cardiovasc Surg Date: 2015-07-30 Impact factor: 5.209
Authors: Eric J Charles; Mary E Huerter; Cynthia E Wagner; Ashish K Sharma; Yunge Zhao; Mark H Stoler; J Hunter Mehaffey; James M Isbell; Christine L Lau; Curtis G Tribble; Victor E Laubach; Irving L Kron Journal: Ann Thorac Surg Date: 2016-09-07 Impact factor: 4.330